Phibro Animal Health Corporation is a diversified global company focused on improving the health, productivity, and welfare of food-producing animals. The business traces its origins to 1946, when it was established as Philipp Brothers Chemicals, Inc. It adopted the Phibro Animal Health name in 2003 and was incorporated in Delaware in 2014, the same year it completed its initial public offering and began trading on NASDAQ under the symbol PAHC. The company is headquartered at Glenpointe Centre East in Teaneck, New Jersey, and operates internationally across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia-Pacific region.
Phibro reports three principal business segments. Animal Health provides pharmaceutical and biological products used by poultry, swine, beef cattle, dairy cattle, and aquaculture producers. Its portfolio includes antimicrobials, anticoccidials for controlling coccidiosis, anthelmintics for intestinal parasites, anti-bloat products for cattle, nutritional supplements, and vaccines, particularly for poultry and swine. These products are intended to help producers prevent disease, manage production risks, and improve animal performance while supporting responsible use of animal health interventions.
The Mineral Nutrition segment manufactures and supplies trace-mineral products and concentrates containing nutrients such as zinc, manganese, copper, and iron. These ingredients are used in animal diets to support growth, immune function, reproduction, and overall nutritional balance. The Performance Products segment supplies specialty ingredients used in areas including personal care, industrial chemicals, and chemical catalysts, providing Phibro with exposure beyond livestock health and nutrition.
The company serves customers through its own sales organizations, direct relationships with integrated poultry, swine, and cattle operations, commercial feed producers, wholesalers, and distributors. Its products are marketed under numerous product lines, giving Phibro a broad portfolio and multi-channel route to market. The company’s stated value proposition centers on science-based research, technical support, and collaboration with farmers, ranchers, veterinarians, nutritionists, and animal production companies.
Daniel Bendheim serves as chief executive officer and president. The company reported approximately 2,475 full-time employees in the supplied financial data, placing it in the 2,001-5,000 employee category. Based on the supplied trailing-twelve-month information, Phibro generated a gross margin of approximately 32.5%, an EBITDA margin of about 15.0%, and a net profit margin near 6.3%. Its reported current ratio of approximately 3.17 indicates substantial current-asset coverage, while debt-to-equity of approximately 2.18 reflects meaningful financial leverage. The company also reported a quarterly-style annualized dividend per share of approximately $0.48 in the supplied data. Key business considerations include livestock production cycles, disease outbreaks, regulatory requirements, raw-material and manufacturing costs, product approvals, currency movements, agricultural demand, and competition in animal health and feed additives. Overall, Phibro’s strategic focus is to remain a trusted partner to animal producers by combining products, technical expertise, research, and global distribution.
Zoetis Inc. (transitional supply agreement)NYSE:ZTSMultiple third-party contract manufacturers (14 facilities)Global API and raw material suppliers (China, India, Europe)SPF egg and biological material suppliersMineral concentrate and micronutrient suppliersPackaging and logistics providersChemical raw material miners and processors (global mining companies)
